Anavex Life Sciences Corp. (0HFR.L)
USD 9.08
(-3.55%)
USD 9.08
(-3.55%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -55.75 Million USD | 5.16% |
| 2022 | -50.94 Million USD | -20.16% |
| 2021 | - USD | -34.17% |
| 2020 | - USD | -7.56% |
| 2019 | - USD | -50.94% |
| 2018 | - USD | -22.92% |
| 2017 | -15.56 Million USD | -3.51% |
| 2016 | -15.01 Million USD | -24.23% |
| 2015 | -7.1 Million USD | -4.42% |
| 2014 | -2.96 Million USD | -442.55% |
| 2013 | -2.13 Million USD | -352.9% |
| 2012 | -8.05 Million USD | 90.83% |
| 2011 | -6.63 Million USD | -84.28% |
| 2010 | -8.49 Million USD | 30.68% |
| 2009 | -5.44 Million USD | 23.46% |
| 2008 | -5.25 Million USD | -233.07% |
| 2007 | -1.57 Million USD | -6056.57% |
| 2006 | -25.41 Thousand USD | 72.02% |
| 2005 | -91.42 Thousand USD | -533.67% |
| 2004 | -14.46 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -12.51 Million USD | 100.0% |
| 2024 Q1 | -11.44 Million USD | 8.61% |
| 2024 Q3 | -14.72 Million USD | 0.0% |
| 2023 Q3 | -11.13 Million USD | 20.84% |
| 2023 FY | - USD | 5.16% |
| 2023 Q2 | -14.07 Million USD | 10.52% |
| 2023 Q1 | -15.72 Million USD | -6.33% |
| 2023 Q4 | -10.02 Million USD | 10.0% |
| 2022 Q3 | -11.72 Million USD | 0.53% |
| 2022 Q1 | -11.77 Million USD | 1.57% |
| 2022 FY | - USD | -20.16% |
| 2022 Q4 | -14.78 Million USD | -26.12% |
| 2022 Q2 | -11.78 Million USD | -0.08% |
| 2021 Q3 | -11.19 Million USD | -27.37% |
| 2021 Q4 | -11.96 Million USD | -6.9% |
| 2021 FY | - USD | -34.17% |
| 2021 Q1 | -9.72 Million USD | -27.05% |
| 2021 Q2 | -8.78 Million USD | 9.66% |
| 2020 Q2 | -7.37 Million USD | 3.99% |
| 2020 FY | - USD | -7.56% |
| 2020 Q3 | -8.35 Million USD | -13.33% |
| 2020 Q4 | -7.65 Million USD | 8.35% |
| 2020 Q1 | -7.67 Million USD | -21.65% |
| 2019 Q2 | -8.11 Million USD | -9.81% |
| 2019 FY | - USD | -50.94% |
| 2019 Q1 | -7.39 Million USD | -27.77% |
| 2019 Q3 | -7.05 Million USD | 13.12% |
| 2019 Q4 | -6.31 Million USD | 10.52% |
| 2018 Q4 | -5.78 Million USD | -27.84% |
| 2018 Q3 | -4.52 Million USD | 4.01% |
| 2018 FY | - USD | -22.92% |
| 2018 Q1 | -4.1 Million USD | 20.62% |
| 2018 Q2 | -4.71 Million USD | -14.91% |
| 2017 Q1 | -3.14 Million USD | 52.35% |
| 2017 FY | - USD | -3.51% |
| 2017 Q3 | -3.64 Million USD | -1.15% |
| 2017 Q2 | -3.6 Million USD | -14.5% |
| 2017 Q4 | -5.17 Million USD | -41.83% |
| 2016 Q4 | -6.6 Million USD | -192.97% |
| 2016 Q1 | -3.9 Million USD | 27.3% |
| 2016 FY | - USD | -24.23% |
| 2016 Q2 | -2.27 Million USD | 41.8% |
| 2016 Q3 | -2.25 Million USD | 0.83% |
| 2015 FY | - USD | -4.42% |
| 2015 Q4 | -5.37 Million USD | -258.02% |
| 2015 Q3 | -1.5 Million USD | -66.44% |
| 2015 Q2 | -901.69 Thousand USD | -23.05% |
| 2015 Q1 | -732.77 Thousand USD | 92.09% |
| 2014 Q4 | -9.26 Million USD | -827.68% |
| 2014 Q3 | -998.64 Thousand USD | 2.19% |
| 2014 Q2 | -1.02 Million USD | -229.97% |
| 2014 FY | - USD | -442.55% |
| 2014 Q1 | -309.41 Thousand USD | 78.93% |
| 2013 Q1 | -415.4 Thousand USD | -112.98% |
| 2013 FY | - USD | -352.9% |
| 2013 Q4 | -1.46 Million USD | -1065.57% |
| 2013 Q2 | -127 Thousand USD | 69.43% |
| 2013 Q3 | -125.98 Thousand USD | 0.8% |
| 2012 Q3 | -695.88 Thousand USD | 12.38% |
| 2012 Q4 | 3.2 Million USD | 559.99% |
| 2012 FY | - USD | 90.83% |
| 2012 Q2 | -794.19 Thousand USD | 64.58% |
| 2012 Q1 | -2.24 Million USD | -102.76% |
| 2011 Q3 | -1.69 Million USD | 12.67% |
| 2011 Q1 | -1.36 Million USD | -7.8% |
| 2011 FY | - USD | -84.28% |
| 2011 Q4 | -1.1 Million USD | 34.91% |
| 2011 Q2 | -1.94 Million USD | -42.36% |
| 2010 FY | - USD | 30.68% |
| 2010 Q4 | -1.26 Million USD | -72.66% |
| 2010 Q3 | -734.25 Thousand USD | 45.82% |
| 2010 Q2 | -1.35 Million USD | -4.44% |
| 2010 Q1 | -1.29 Million USD | 20.22% |
| 2009 Q1 | -914.92 Thousand USD | 69.85% |
| 2009 Q2 | -320.05 Thousand USD | 65.02% |
| 2009 Q3 | -1.17 Million USD | -268.68% |
| 2009 Q4 | -1.62 Million USD | -37.85% |
| 2009 FY | - USD | 23.46% |
| 2008 Q3 | -671.7 Thousand USD | -1.55% |
| 2008 Q2 | -661.45 Thousand USD | 27.85% |
| 2008 FY | - USD | -233.07% |
| 2008 Q1 | -916.74 Thousand USD | 19.64% |
| 2008 Q4 | -3.03 Million USD | -351.72% |
| 2007 Q3 | -255.56 Thousand USD | -51.29% |
| 2007 FY | - USD | -6056.57% |
| 2007 Q2 | -168.92 Thousand USD | -1264.14% |
| 2007 Q4 | -1.14 Million USD | -346.37% |
| 2007 Q1 | -12.38 Thousand USD | -111.86% |
| 2006 Q3 | -5680.00 USD | -21.89% |
| 2006 Q4 | -5845.00 USD | -2.9% |
| 2006 FY | - USD | 72.02% |
| 2006 Q1 | -9407.00 USD | 77.43% |
| 2006 Q2 | -4660.00 USD | 50.46% |
| 2005 FY | - USD | -533.67% |
| 2005 Q3 | -45.69 Thousand USD | 0.0% |
| 2005 Q2 | -45.69 Thousand USD | -1015.13% |
| 2005 Q4 | -41.67 Thousand USD | 8.81% |
| 2005 Q1 | -4098.00 USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 65.818% |
| Dynavax Technologies Corporation | 9.66 Million USD | 676.826% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 156.742% |
| Perrigo Company plc | 646.2 Million USD | 108.628% |
| Illumina, Inc. | -608 Million USD | 90.83% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.516% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 87.583% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.506% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 101.712% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 46.281% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 101.198% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -49.548% |
| Waters Corporation | 1.02 Billion USD | 105.454% |
| Biogen Inc. | 2.37 Billion USD | 102.346% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 36.226% |
| Evolus, Inc. | -41.81 Million USD | -33.356% |
| Adicet Bio, Inc. | -136.53 Million USD | 59.164% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 52.609% |
| bluebird bio, Inc. | -167.16 Million USD | 66.645% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 62.856% |
| FibroGen, Inc. | -261.4 Million USD | 78.671% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 103.325% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -25.473% |
| Homology Medicines, Inc. | -47.75 Million USD | -16.752% |
| Geron Corporation | -174.78 Million USD | 68.1% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 75.559% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 39.448% |
| Myriad Genetics, Inc. | -67.8 Million USD | 17.764% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 44.701% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 88.988% |
| Zoetis Inc. | 3.68 Billion USD | 101.513% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -10.251% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 104.79% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 117.969% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 101.211% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -54.526% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 75.759% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 79.039% |
| Verastem, Inc. | -83.16 Million USD | 32.958% |
| Nektar Therapeutics | -243.1 Million USD | 77.065% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 75.219% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 36.63% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 87.305% |
| OPKO Health, Inc. | -65.51 Million USD | 14.897% |
| Exelixis, Inc. | 196.6 Million USD | 128.36% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 113.4% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 151.472% |
| uniQure N.V. | -253.1 Million USD | 77.971% |
| Imunon, Inc. | -20.78 Million USD | -168.286% |
| Blueprint Medicines Corporation | -474.61 Million USD | 88.252% |
| Insmed Incorporated | -654.73 Million USD | 91.484% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 112.337% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 83.861% |
| TG Therapeutics, Inc. | 26.1 Million USD | 313.625% |
| Incyte Corporation | 919.42 Million USD | 106.064% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 88.966% |